List of Excipients in Branded Drug DESOWEN

Generic Drugs Containing DESOWEN

Company	Ingredient	NDC	Excipient
Galderma Laboratories LP	desonide	0299-5770	ANHYDROUS CITRIC ACID
Galderma Laboratories LP	desonide	0299-5770	ISOPROPYL PALMITATE
Galderma Laboratories LP	desonide	0299-5770	POLYSORBATE 60
Galderma Laboratories LP	desonide	0299-5770	POTASSIUM SORBATE
Galderma Laboratories LP	desonide	0299-5770	PROPYL GALLATE

What are the Most Frequently-Used Excipients in DESOWEN?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	ISOPROPYL PALMITATE
1	POLYSORBATE 60
1	POTASSIUM SORBATE
1	PROPYL GALLATE

DESOWEN Excipient Strategy and Commercial Opportunities for Desonide Topical Products

Last updated: September 5, 2026

DesOwen is a topical corticosteroid brand containing desonide 0.05%. Its commercial opportunity is primarily generic and formulation-led. The strongest opportunities are low-irritancy cream, ointment, lotion, gel, foam, and preservative-optimized products that improve tolerability, application feel, packaging, or use on sensitive skin. Desonide is a low-potency corticosteroid, so differentiation depends more on excipient performance, vehicle selection, dermatology positioning, and channel execution than on active-ingredient exclusivity.

What is DesOwen and which formulations are commercially relevant?

DesOwen products use desonide 0.05% for corticosteroid-responsive dermatoses. The historical product family includes cream, ointment, and lotion presentations. Desonide is generally positioned as a low-potency topical corticosteroid for inflammatory skin conditions where a lower-strength steroid is preferred.[1]

Product type	Active ingredient	Typical commercial role	Excipient priorities
Cream	Desonide 0.05%	Broadest retail and dermatology use	Spreadability, low residue, preservative tolerance
Ointment	Desonide 0.05%	Dry, thickened, or highly occlusive-use applications	Occlusion, emolliency, water resistance
Lotion	Desonide 0.05%	Hair-bearing areas and larger surface areas	Low tack, pumpability, rapid spreading
Gel or hydrogel	Desonide 0.05%	Potential differentiated generic or Rx-to-OTC-style format	Cooling, low residue, alcohol tolerance
Foam or spray	Desonide 0.05%	Scalp and difficult-to-reach areas	Propellant compatibility, deposition, scalp feel

The formulation must preserve corticosteroid delivery through the stratum corneum while limiting irritation, stinging, drying, tackiness, and cosmetic residue. For a low-potency corticosteroid, the vehicle can materially influence patient acceptance and practical effectiveness.

What excipients are used in DesOwen-type formulations?

DesOwen labeling and comparable desonide products identify conventional dermatologic excipients such as purified water, mineral oil, petrolatum, fatty alcohols, glyceryl stearate, PEG stearates, polysorbates, propylene glycol, and preservatives, depending on the dosage form.[1,2]

The excipient system typically performs five functions:

1. Solubilizes or disperses desonide.
2. Builds viscosity and physical stability.
3. Supports skin hydration and drug partitioning.
4. Controls sensory characteristics.
5. Protects the product from microbial contamination and oxidation.

Cream excipient architecture

A cream generally uses an oil-in-water or water-continuous emulsion. Common structural components include:

• Purified water as the continuous phase.
• Mineral oil or another emollient oil phase.
• Petrolatum for occlusivity.
• Glyceryl stearate and PEG stearates as emulsifiers.
• Cetyl and stearyl alcohol as consistency agents.
• Polysorbates or sorbitan esters for emulsion stability.
• Propylene glycol as a humectant and cosolvent.
• Parabens or alternative preservatives.

The commercial objective is a cream that spreads quickly, absorbs without excessive residue, and remains stable through its labeled shelf life. A generic that matches the reference product's appearance and sensory profile is more likely to obtain dermatologist and pharmacy acceptance than a product that is technically bioequivalent but visibly or sensorially different.

Ointment excipient architecture

An ointment normally relies on petrolatum, mineral oil, or related hydrocarbon bases. The principal advantages are occlusion, skin softening, and water resistance. The principal disadvantages are greasiness, low cosmetic acceptance, and poor suitability for hair-bearing sites.

The key formulation risk is not chemical complexity but patient adherence. A highly occlusive ointment may provide strong barrier performance while generating lower use frequency or lower willingness to apply the product.

Lotion excipient architecture

A lotion generally emphasizes:

• Low viscosity.
• Rapid spreading.
• Pump or pour dispensing.
• Lower residue than an ointment.
• Applicability to larger body areas.

Lotion systems can face greater physical-stability risk than ointments. Emulsion separation, viscosity drift, microbial growth, and pump compatibility require controlled development and stability testing.

What excipient strategy should a DesOwen generic use?

The most defensible strategy is a platform approach with one reference-aligned product and one differentiated product.

Platform 1: Reference-aligned cream

The first product should reproduce the reference product's major physical attributes:

• White to off-white appearance.
• Comparable viscosity.
• Comparable spreadability.
• Similar drying time.
• Similar fragrance profile, preferably low-odor or odorless.
• Similar packaging and dispensing behavior.
• Comparable preservative performance.

This product is designed for regulatory efficiency and substitution. Its excipient composition should avoid unnecessary innovation that could create additional safety, stability, or bioequivalence risks.

Platform 2: Sensitive-skin cream

A second product can target patients who experience stinging or irritation from conventional vehicles. The formulation can emphasize:

• Reduced or zero propylene glycol.
• Lower fragrance and allergen burden.
• Alternative preservative systems.
• Lower surfactant loading.
• Barrier-supportive emollients.
• Controlled pH near the skin's natural acidic range.
• Reduced ethanol content or an alcohol-free system.

A sensitive-skin formulation may command a higher price if the manufacturer can demonstrate better tolerability without reducing delivery performance.

Platform 3: Lightweight lotion or gel

A lotion or gel can target:

• Scalp and hair-bearing skin.
• Intertriginous areas.
• Pediatric caregivers seeking lower mess.
• Larger treatment areas.
• Patients who reject greasy products.

A hydroalcoholic gel may provide rapid drying and low residue, but alcohol can increase stinging on inflamed or fissured skin. A water-rich hydrogel can reduce that concern but may require stronger preservation and more complex rheology control.

Which excipients create the largest commercial differentiation?

Propylene glycol

Propylene glycol is useful as a humectant, solvent, and penetration-supporting excipient. It can also cause stinging or irritation in some patients. A propylene-glycol-free formulation has a clear marketing rationale for sensitive skin, but removing it may affect desonide solubilization, release, viscosity, and preservative performance.

A developer should not treat propylene glycol removal as a simple substitution. The replacement may require changes to the oil phase, surfactant system, pH, particle size, and manufacturing process.

Preservatives

Preservative strategy is a major differentiator in topical products. Parabens are effective and familiar but may be commercially disfavored by some consumers and retailers. Phenoxyethanol, organic acids, benzyl alcohol, and multifunctional excipients provide alternatives, each with different pH, compatibility, and irritation profiles.

Preservative changes can affect:

• Microbial limits.
• Container compatibility.
• Extractables and leachables.
• Skin tolerability.
• Regulatory comparability.
• Shelf life.

A preservative-free multidose cream is generally difficult because repeated patient use creates contamination risk. Single-dose or unit-dose packaging can address that risk but raises cost and reduces convenience.

Petrolatum and mineral oil

Petrolatum provides strong occlusion and is well established in dermatology. Mineral oil improves emolliency and spreadability. These ingredients are inexpensive and robust, but they reduce the opportunity for premium positioning.

A manufacturer can use a lighter ester, silicone, or synthetic emollient system to improve sensory performance. That approach may increase raw-material cost and create a more complex regulatory and supply-chain profile.

Fatty alcohols and emulsifiers

Cetyl alcohol, stearyl alcohol, glyceryl stearate, PEG stearates, polysorbates, and sorbitan esters determine emulsion structure and texture. Small changes can affect:

• Rub-in time.
• White cast.
• Flaking.
• Phase separation.
• Viscosity.
• Drug release.

These excipients are often the hidden drivers of perceived product quality. A technically compliant product with poor rub-in or pilling can lose share despite a lower acquisition cost.

What patents protect DesOwen and desonide formulations?

DesOwen's core commercial opportunity is not dependent on a newly patented desonide molecule. Desonide is an established corticosteroid, and generic competition exists across multiple topical dosage forms.

Potential protection categories include:

Protection category	Relevance to DesOwen-type products	Commercial effect
Active ingredient patent	Low for established desonide	Usually does not block current generic development
Composition patent	May cover a specific cream, lotion, gel, or foam	Can create formulation-specific barriers
Method-of-use patent	May cover a particular disease, population, or dosing method	Can affect labeling and carve-out strategy
Manufacturing patent	May cover particle size, mixing, homogenization, or process controls	Can require a non-infringing process
Device or package patent	May cover pump, dispenser, metered delivery, or applicator	Can affect presentation and substitution
Trade secret	Often relevant to process parameters and scale-up	Can impede direct replication without creating public patent rights

An ANDA sponsor must evaluate current Orange Book listings, patent certifications, listed use patents, and litigation records for the specific reference product and dosage form.[3] A patent search limited to the DesOwen brand name may miss patents assigned to prior owners, formulation licensors, or companies marketing authorized generics.

What is the Orange Book status of DesOwen?

The Orange Book is the controlling FDA source for listed patents, exclusivity, therapeutic equivalence evaluations, and reference-product information.[3] DesOwen-related status must be reviewed by dosage form and strength because cream, ointment, lotion, gel, and other presentations can have different regulatory records.

For an ANDA strategy, the relevant questions are:

• Which product is the current reference listed drug?
• Is the product listed as a reference standard?
• Are there active patents listed for the specific strength and dosage form?
• Are any listed patents method-of-use patents?
• Is pediatric exclusivity or other statutory exclusivity active?
• Does the proposed product qualify for a paragraph III or paragraph IV certification?
• Does the label require a carve-out for a patented use?

Desonide products do not present biosimilar risk because desonide is a small-molecule drug, not a biologic. The relevant competitive pathway is the ANDA process, not the 351(k) biosimilar pathway.

When does DesOwen lose exclusivity and what generic entry risks exist?

The core molecule and conventional vehicles are mature. Generic entry risk is therefore high where the reference product has no blocking patent or exclusivity barrier.

The main entry scenarios are:

Scenario 1: Conventional generic cream

This is the highest-probability entry model. The product competes on:

• Wholesale acquisition cost.
• Pharmacy substitution.
• Formulary placement.
• Supply reliability.
• Tube size.
• Retail availability.

Margin pressure is usually strongest in a conventional cream because multiple manufacturers can offer comparable products.

Scenario 2: Authorized generic

An authorized generic can preserve brand-owner participation while reducing the price gap. It may be marketed under a private-label or generic label and can use the brand product's established manufacturing base.

Scenario 3: Differentiated formulation

A formulation with improved cosmetic profile, lower irritancy, a novel dispenser, or a new vehicle can compete outside pure price substitution. Depending on its design, it may require an ANDA, a suitability petition, a 505(b)(2) application, or another regulatory pathway.

Scenario 4: Dermatology channel product

A manufacturer can focus on dermatologist samples, specialty pharmacy, pediatric dermatology, and teledermatology. This strategy depends on product differentiation and field access rather than patent exclusivity.

Which companies are challenging DesOwen?

Desonide generic competition has historically included multiple manufacturers across topical dosage forms. The relevant competitive set includes generic dermatology companies, contract manufacturers, and branded topical specialists.

Competitive review should compare:

• Product availability by dosage form.
• Tube and bottle sizes.
• NDC count.
• National Drug Code package configuration.
• Retail and mail-order access.
• Backorder history.
• Wholesale pricing.
• Therapeutic-equivalence coding.
• Label differences.
• Preservative and excipient composition.

FDA Drugs@FDA, the Orange Book, DailyMed, and commercial NDC databases are the principal sources for current competitor identification.[1,3,4] Manufacturer participation can change through discontinuations, acquisitions, private-label agreements, and supply decisions.

What formulation patents could create a new commercial opportunity?

A new formulation may support patent protection when it contains a specific, non-obvious combination of:

• Desonide particle-size control.
• A defined solvent or cosolvent system.
• A low-irritancy preservative system.
• A particular emulsion phase ratio.
• A polymeric gel network.
• A foam or aerosol delivery system.
• A metered-dose dispenser.
• A controlled-release or sustained-deposition vehicle.
• A composition that improves delivery while reducing systemic exposure or local irritation.

Patent strength depends on claim breadth, prior art, reproducibility, analytical methods, and the ability to detect infringement. A narrow excipient ratio claim may be easy to design around. A broader composition or delivery-platform patent can be more valuable if it survives enablement and written-description challenges.

Manufacturing patents may have more practical value than composition patents if the process creates a measurable product attribute, such as particle-size distribution, globule size, rheology, or desonide uniformity.

How does DesOwen compare with competing topical corticosteroids?

Desonide competes with other low-potency topical corticosteroids, especially hydrocortisone products. It also competes indirectly with stronger corticosteroids and nonsteroidal topical therapies.

Attribute	Desonide 0.05%	Hydrocortisone	Medium-potency steroids
Typical potency positioning	Low	Low	Higher
Main vehicle opportunity	Cream, lotion, ointment, gel	Broad OTC and Rx range	Cream, ointment, solution, foam
Pediatric and sensitive-skin positioning	Strong	Strong	More limited
Price pressure	High from generics	Very high, including OTC	Variable
Differentiation potential	Vehicle and tolerability	Packaging and OTC positioning	Delivery system and efficacy
Patent opportunity	Formulation and device	Limited for mature products	Product-specific formulations

Desonide's commercial position benefits from a balance between low potency and prescription dermatology use. A manufacturer should avoid competing only on price against hydrocortisone. A cleaner vehicle, better dispenser, or improved scalp application can create a more defensible position.

What regulatory strategy applies to a DesOwen generic?

The conventional route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product. Topical products create special development issues because systemic pharmacokinetic testing may not adequately characterize local performance.

FDA topical dermatological guidance recognizes multiple tools, including comparative physicochemical characterization, in vitro release testing, and, where applicable, in vivo studies.[5] The development plan should control:

• Assay and content uniformity.
• Particle size and polymorphic form.
• Globule size for emulsions.
• Rheology and viscosity.
• pH.
• Spreadability.
• Water activity.
• In vitro release rate.
• Microbial limits.
• Preservative effectiveness.
• Container-closure compatibility.
• Stability under accelerated and long-term conditions.

A major regulatory risk is an excipient change that improves marketing appeal but moves the product outside the reference product's Q1/Q2 composition or creates a materially different release profile.

What licensing deals and commercial partnerships are relevant?

The most practical deal structures are:

1. Reference-product acquisition: Purchase of an established topical product or NDA.
2. ANDA licensing: License an approved or late-stage desonide ANDA from a dermatology manufacturer.
3. Private-label supply: Manufacture for retailers, telehealth platforms, or specialty pharmacies.
4. Excipient technology license: Use a proprietary low-irritancy emulsion, hydrogel, foam, or preservative platform.
5. Regional distribution: Grant rights for selected countries where topical desonide competition remains limited.
6. Co-development: Share development costs for a differentiated vehicle and divide geographic rights.

A licensing target should be valued on product availability, remaining regulatory work, formulation similarity, manufacturing capacity, supply history, and patent encumbrance. A formulation patent without reliable commercial-scale manufacturing has limited standalone value.

What is the revenue exposure and market opportunity?

The conventional desonide cream market is likely to experience price compression as generic supply increases. Revenue opportunity is greater in differentiated formats than in commodity cream.

The most attractive commercial segments are:

• Pediatric dermatology.
• Sensitive-skin patients.
• Scalp and hair-bearing areas.
• Large-area application.
• Patients with poor adherence to greasy ointments.
• Teledermatology and digital pharmacy.
• Cash-pay dermatology.
• Private-label dermatology portfolios.

Revenue drivers include prescription volume, average selling price, reimbursement status, pharmacy substitution, supply continuity, and product mix. A manufacturer with a standard cream, a low-irritancy cream, and a lotion can capture more use cases than a single commodity tube.

How strong is the DesOwen patent estate?

The molecule-level patent position is weak as a barrier because desonide is mature. The strongest potential protection lies in product-specific formulation, delivery, packaging, and manufacturing claims.

Estate component	Relative strength
Desonide active ingredient	Weak
Conventional cream composition	Weak to moderate
Novel excipient combination	Moderate if technically supported
Foam, gel, or metered delivery	Moderate to strong, depending on claims
Manufacturing process	Moderate where product attributes are measurable
Method of use	Variable and often vulnerable to label carve-outs
Trade secrets	Operationally valuable but not a blocking public right

Patent diligence should include U.S. and foreign family members, continuations, terminal disclaimers, assignments, reexaminations, post-grant proceedings, and litigation history. Geographic protection may remain relevant in Canada, Europe, Japan, and selected emerging markets even when U.S. composition protection has expired.

Key Takeaways

• DesOwen contains desonide 0.05%, a mature low-potency topical corticosteroid.
• Generic entry risk is high for conventional cream, ointment, and lotion products.
• Excipient selection is the main route to commercial differentiation.
• The strongest product concepts are low-irritancy cream, lightweight lotion, scalp gel, and patient-friendly foam.
• Propylene glycol, preservatives, emulsifiers, petrolatum, and sensory modifiers require deliberate optimization.
• A reference-aligned cream should generally precede a differentiated formulation.
• Desonide has no biosimilar risk; competition proceeds through small-molecule generic pathways.
• Formulation, device, and manufacturing patents are more relevant than active-ingredient patents.
• Licensing value depends on regulatory readiness, manufacturing reliability, formulation differentiation, and current Orange Book status.
• A three-product portfolio can reduce exposure to commodity pricing: standard cream, sensitive-skin cream, and lightweight lotion or gel.

FAQs

Is DesOwen a steroid cream or an antibiotic?

DesOwen is a topical corticosteroid containing desonide 0.05%. It is not an antibiotic.

Can a preservative-free desonide cream be commercially viable?

Yes, but multidose packaging creates contamination-control challenges. Unit-dose packaging, airless pumps, or validated preservative-free systems can support the concept.

What is the best excipient for improving desonide skin delivery?

No single excipient is universally optimal. Solvents, glycols, emollients, surfactants, and the emulsion structure must be optimized together against release, irritation, stability, and sensory targets.

Is a desonide foam more defensible than a desonide cream?

Potentially. A foam can offer stronger differentiation through delivery, packaging, and scalp usability, but it creates greater manufacturing, device, flammability, and regulatory complexity.

Can a generic manufacturer avoid a desonide method-of-use patent?

An ANDA sponsor may use an appropriate patent certification and, where permitted, a label carve-out for patented indications or dosing instructions. The strategy depends on the current Orange Book listing and the scope of the asserted claims.

References

1. National Library of Medicine. (n.d.). DailyMed: Desonide topical products and prescribing information. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (n.d.). National Drug Code directory. https://www.accessdata.fda.gov/scripts/cder/ndc/
5. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatological drug product development and abbreviated new drug application submissions. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/topical-dermatological-drug-product-development-and-abbreviated-new-drug-application-submissions